Issue 2/2018
Content (30 Articles)
Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Hehui Fang, Doudou Huang, Fang Yang, Xiaoxiang Guan
Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis
E. A. Underwood, P. A. Rochon, R. Moineddin, P. E. Lee, W. Wu, K. I. Pritchard, M. C. Tierney
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition
E. Santana dos Santos, S. M. Caputo, L. Castera, M. Gendrot, A. Briaux, M. Breault, S. Krieger, P. K. Rogan, E. J. Mucaki, L. J. Burke, I. Bièche, C. Houdayer, D. Vaur, D. Stoppa-Lyonnet, M. A. Brown, F. Lallemand, E. Rouleau
Enrichment of high-grade tumors in breast cancer gene expression studies
M. van Seijen, A. L. Mooyaart, L. Mulder, M. Hoogstraat, C. A. Drukker, C. E. Loo, B. Pouw, G. S. Sonke, J. Wesseling, E. H. Lips
Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
Y. F. Yu, Y. Wang, T. P. Fu, K. Chen, J. Q. Liu, H. R. Yao
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Alexios Matikas, Sara Margolin, Mats Hellström, Hemming Johansson, Nils-Olof Bengtsson, Lena Karlsson, Per Edlund, Per Karlsson, Elisabet Lidbrink, Barbro Linderholm, Henrik Lindman, Per Malmstrom, Kenneth Villman, Theodoros Foukakis, Jonas Bergh
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli, T. Pluard, A. Urruticoechea, D. Farci, A. Kong, T. Bachelot, S. Chan, H. S. Han, G. Jerusalem, P. Urban, D. Robinson, S. L. Mouhaër, E. D. Tomaso, C. Massacesi, C. Saura
99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis
Jiwei Wang, Tie Fan, Yingjian He, Xue Chen, Zhaoqing Fan, Yuntao Xie, Tianfeng Wang, Jinfeng Li, Tao Ouyang
A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer
Mohammed F. K. Ibrahim, John Hilton, Sasha Mazzarello, Dean Fergusson, Brian Hutton, Andrew Robinson, Nadia Califaretti, Tina Hsu, Stan Gertler, Mihaela Mates, Carol Stober, Lisa Vandermeer, Ranjeeta Mallick, Mark Clemons
A single institution experience with palbociclib toxicity requiring dose modifications
Jun Gong, May Cho, Kim Wai Yu, James Waisman, Yuan Yuan, Joanne Mortimer
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Jie Xie, Jun Cao, Jing-fen Wang, Bai-hong Zhang, Xiao-hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-dong Wu, Qiang Yao, Xiao-chun Zhao, Wei-dong Mao, Ai-Mei Jiang, Shao-shui Chen, Shun-e Yang, Shu-sen Wang, Jian-hong Wang, Yue-yin Pan, Bi-yong Ren, Yan-ju Chen, Li-zhi Ouyang, Kai-jian Lei, Jing-hua Gao, Wen-he Huang, Zhan Huang, Tao Shou, Yan-ling He, Jing Cheng, Yang Sun, Wei-ming Li, Shu-de Cui, Xin Wang, Zhi-guo Rao, Hu Ma, Wei Liu, Xue-yong Wu, Wei-xi Shen, Fei-lin Cao, Ze-min Xiao, Biao Wu, Shu-yan Tian, Dong Meng, Peng Shen, Bi-yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Xi-chun Hu
CD14+ HLA-DR−/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation
Lisa Speigl, Helen Burow, Jithendra Kini Bailur, Nicole Janssen, Christina-Barbara Walter, Graham Pawelec, Christopher Shipp
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
Erik J. Blok, Judith R. Kroep, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Hein Putter, Gerrit-Jan Liefers, Johan W. R. Nortier, Emiel J. Th. Rutgers, Caroline M. Seynaeve, Cornelis J. H. van de Velde
Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy
Jonna K. van Vulpen, Martina E. Schmidt, Miranda J. Velthuis, Joachim Wiskemann, Andreas Schneeweiss, Roel C. H. Vermeulen, Nina Habermann, Cornelia M. Ulrich, Petra H. M. Peeters, Elsken van der Wall, Anne M. May, Karen Steindorf
Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work
Claire Falandry, Ivan Krakowski, Hervé Curé, Elisabeth Carola, Pierre Soubeyran, Olivier Guérin, Hélène Gaudin, Gilles Freyer
Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study
Zhiyu Xia, Kathy B. Baumgartner, Richard N. Baumgartner, Stephanie D. Boone, Lisa M. Hines, Esther M. John, Roger Wolff, Martha L. Slattery, Avonne E. Connor
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer
T. Reinert, M. Debiasi, J. Bines, C. H. Barrios
Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors
Sarah J. O. Nomura, Yi-Ting Hwang, Scarlett Lin Gomez, Teresa T. Fung, Shu-Lan Yeh, Chiranjeev Dash, Laura Allen, Serena Philips, Leena Hilakivi-Clarke, Yun-Ling Zheng, Judy Huei-yu Wang
Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors
Sarah J. O. Nomura, Yi-Ting Hwang, Scarlett Lin Gomez, Teresa T. Fung, Shu-Lan Yeh, Chiranjeev Dash, Laura Allen, Serena Philips, Leena Hilakivi-Clarke, Yun-Ling Zheng, Judy Huei-yu Wang
Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy
Wentao Li, Carol Chi-Hei Kwok, Dominic Chun-Wan Chan, Feng Wang, Lap Ah Tse
Worse survival after breast cancer in women with anorexia nervosa
Annet Bens, Fotios C. Papadopoulos, Eero Pukkala, Anders Ekbom, Mika Gissler, Lene Mellemkjær
Analysis of breast cancer in young women in the Department of Defense (DOD) database
Alexandra S. Zimmer, Kangmin Zhu, Patricia S. Steeg, Alex Wu, Margaret E. Gatti-Mays, Sanaz Soltani, Jeremy G. Perkins, Stephanie Shao, Derek Brown, Matthew Georg, Hai Hu, Craig D. Shriver, Stanley Lipkowitz
Predictors of survival for breast cancer patients with a BRCA1 mutation
Steven A. Narod, Tomasz Huzarski, Jacek Gronwald, Tomasz Byrski, Elzbieta Marczyk, Cezary Cybulski, Marek Szwiec, Rafal Wisniowski, Bozena Birkenfeld, Ewa Kilar, Robert Sibilski, Ping Sun, Jan Lubinski
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy
Marilyn L. Kwan, Song Yao, Cecile A. Laurent, Janise M. Roh, Charles P. Quesenberry Jr., Lawrence H. Kushi, Joan C. Lo
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
Zhe Wang, Jing Kong, Ying Wu, Juliang Zhang, Ting Wang, Nanlin Li, Jing Fan, Hui Wang, Jian Zhang, Rui Ling
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA
Ciyu Yang, Sowmya Jairam, Kimberly A. Amoroso, Mark E. Robson, Michael F. Walsh, Liying Zhang
Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy
S. N. Han, F. Amant, E. H. Cardonick, S. Loibl, F. A. Peccatori, O. Gheysens, C. A. Sangalli, V. Nekljudova, K. Dahl Steffensen, M. Mhallem Gziri, C. P. Schröder, C. A. R. Lok, A. Verest, P. Neven, A. Smeets, G. Pruneri, M. Cremonesi, O. Gentilini
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
Pauline du Rusquec, Clément Palpacuer, Loic Campion, Anne Patsouris, Paule Augereau, Carole Gourmelon, Marie Robert, Laurence Dumas, Folliard Caroline, Mario Campone, Jean-Sébastien Frenel
Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort
Catherine Duggan, Richard N. Baumgartner, Kathy B. Baumgartner, Leslie Bernstein, Stephanie George, Rachel Ballard, Marian L. Neuhouser, Anne McTiernan
Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
Alejandra F. Pichilingue-Febres, Miguel A. Arias-Linares, Roger V. Araujo-Castillo